Astellas plans to keep some jobs in Farmingdale; Synergy touts PhIIa constipation data;

 @FierceBiotech: The 2010 Biotech Graveyard. Article | Follow @FierceBiotech

 @JohnCFierce: Sequencing upstart Pacific Biosciences outlines pricing of $230M IPO. Story |  Follow @JohnCFierce

Special Report: Big Pharma behaving badly: A timeline of settlements

> Tumor cells offer 'real-time' snapshot of cancer status. Story

> Researchers tout accuracy of new prostate cancer biomarker. Report

> Astellas has confirmed that it will keep 90 of the 240 employees at OSI Pharmaceuticals' operations in Farmingdale, NY. "By providing OSI employees with more clarity regarding the plans for the integration and organizational decisions, we hope to minimize their uncertainty," Astellas says, as quoted by the Long Island Business News. Report

> Synergy Pharmaceuticals says it garnered positive results from a Phase IIa clinical trial of plecanatide (SP-304) in patients with chronic constipation. Synergy release

> Banyan scores $26.3M DoD contract for TBI test. News

> Sources tell Reuters that Japan's Kyowa Hakko Kirin plans to sell its chemical unit for up to $720 million. Story

> Former stockholders for Quill Medical have filed suit against Angiotech, claiming that the biotech company breached its 2006 merger agreement. Anuitech bought Quill for $40 million plus milestones. Item

And Finally... Billions of brain cells are communicating at any given moment. Like an organic supercomputer they keep everything going, from breathing to solving riddles, and "programming errors" can lead to serious conditions such as schizophrenia, Parkinson's Disease and attention-deficit hyperactivity disorder. Release

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.